Synthetic Biology is an emerging area of biotech thats clearly outperforming the broader biotech sector this year. (NASDAQ:IBB +31% YTD) Stocks surging in this space include ZIOPHARM Oncology (ZIOP), Intrexon (XON), and Synthetic Biologics (SYN). On average the three are up 167% YTD while the Nasdaq's biotech index (IBB) is up 31%. Definitely worth keeping an eye on.